 This is a European multinational, multicenter, non-interventional observational and prospective study. It is carried on to confirm in real life conditions the benefitrisk of vandetanib CAPRELSATM 300 mg, both in RET negative and RET positive patients with symptomatic, aggressive, sporadic, unresectable, locally advancedmetastatic MTC. 